NEW YORK, Jan 5 – Genomics Collaborative, a SNP-detection company, said Friday it has appointed Michael Dougherty as president and chief operating officer.
Dougherty was previously president and CEO of biotech company Magainin Pharmaceuticals, where he will remain non-executive chairman of the board.
“We view Michael’s arrival as another step toward CGI positioning itself to develop genomic based products,” CEO Michael Pellini said in a statement.
Based in Cambridge, Mass., Genomics Collaborative is a privately held company that recently raised $36 million from investors including Invesco Private Capital, Oracle Partners, AFTC Funds, and the Economic Development Board of Singapore.
The company has partnership agreements with companies such as Lynx Therapeutics, Gene Logic, Qiagen, and Genometrix.